- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05714085
Effekt, sikkerhet og farmakokinetikk av Vericiguat hos pediatriske deltakere med hjertesvikt på grunn av venstre ventrikkels systolisk dysfunksjon (MK-1242-036)
En fase 2/3 randomisert, placebokontrollert, dobbeltblind, klinisk studie for å evaluere effektiviteten, sikkerheten og farmakokinetikken til Vericiguat hos pediatriske deltakere med hjertesvikt på grunn av systemisk venstre ventrikkel systolisk dysfunksjon (VALOR)
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Studieoversikt
Status
Detaljert beskrivelse
As of Protocol Amendment 2, the separate open-label extension arm of study MK-1242-043 (NCT06428383) will be incorporated into the present MK-1242-036 study as an extension period. Participants from the Base Period will be provided the opportunity to participate in the optional open-label Extension Period if eligible. After all ongoing participants are transferred into the extension period of MK-1242-036, MK-1242-043 (NCT06428383) will be formally closed.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-post: Trialsites@msd.com
Studiesteder
-
-
Liege
-
Liège, Liege, Belgia, 4000
- Fullført
- Centre Hospitalier Régional de la Citadelle ( Site 0302)
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgia, 9000
- Rekruttering
- UZ Gent ( Site 0301)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +32 9 332 24 30
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgia, 3000
- Rekruttering
- UZ Leuven ( Site 0300)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +32 16 34 59 98
-
-
-
-
-
São Paulo, Brasil, 05403-900
- Rekruttering
- Incor - Instituto do Coracao ( Site 0400)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +55 11 2661 5450
-
-
São Paulo
-
São Paulo, São Paulo, Brasil, 04012-909
- Rekruttering
- Instituto Dante Pazzanese de Cardiology ( Site 0402)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 55 11 5085 6866
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Rekruttering
- Stollery Children's Hospital ( Site 0501)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 780-407-1586
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Rekruttering
- The Hospital for Sick Children ( Site 0500)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 416-813-1500
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5H4
- Rekruttering
- Centre intégré universitaire de santé et de services sociaux-Centre de recherche du CHUS ( Site 0502)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 819-346-1110, 12889
-
-
-
-
Antioquia
-
Rionegro, Antioquia, Colombia, 054040
- Rekruttering
- Clinica Somer ( Site 0607)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 57 3125891661
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 08001
- Rekruttering
- Ciensalud Ips S A S ( Site 0608)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +573506961481
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Colombia, 110131
- Rekruttering
- Fundación Cardioinfantil Instituto de Cardiología ( Site 0603)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 6017563426 EXT 73205
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760032
- Rekruttering
- Fundación Valle del Lili ( Site 0604)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +573133288646
-
Cali, Valle del Cauca Department, Colombia, 760042
- Rekruttering
- Clínica Imbanaco S.A.S ( Site 0602)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +573117441693
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Danmark, DK-2100
- Rekruttering
- Rigshospitalet-BørneUngeAfdelingen ( Site 0800)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +45 35453545
-
-
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Finland, 33520
- Rekruttering
- Tampereen yliopistollinen sairaala-Pediatric Early Phase Trials Unit ( Site 0900)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +358503539956
-
-
-
-
California
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 310-825-9111
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- Lucile Packard Children's Hospital ( Site 0040)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 650-721-2121
-
San Bernardino, California, Forente stater, 92408
- Rekruttering
- Loma Linda University Health System ( Site 0008)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 909-558-5830
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Fullført
- Children's Hospital Colorado ( Site 0012)
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- Children's National Medical Center ( Site 0020)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 888-884-2327
-
-
Florida
-
St. Petersburg, Florida, Forente stater, 33701
- Rekruttering
- Johns Hopkins All Children's Hospital ( Site 0029)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 727-898-7451
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 404-785-0381
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Boston Children's Hospital ( Site 0035)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 617-355-4213
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- C.S. Mott Children's Hospital ( Site 0033)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 734-615-0590
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 800-678-4357
-
-
New York
-
New York, New York, Forente stater, 10032
- Rekruttering
- Columbia University Medical Center-Pediatric Cardiology ( Site 0016)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 212-305-5437
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- The Children's Hospital at Montefiore ( Site 0030)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 718-741-2426
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center ( Site 0034)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 513-636-3016
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 216-444-2200
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia (CHOP) ( Site 0004)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 215-590-1000
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- Children's Hospital of Pittsburgh ( Site 0010)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 412-692-5325
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38103
- Rekruttering
- Le Bonheur Children's Hospital ( Site 0007)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 901-287-5760
-
-
Texas
-
Dallas, Texas, Forente stater, 75235
- Rekruttering
- Children's Health-The Heart Center ( Site 0015)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 214-456-7000
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Texas Children's Hospital ( Site 0039)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 832-826-2806
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 206-987-2015
-
-
-
-
-
Paris, Frankrike, 75019
- Fullført
- Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universita ( Site 1004)
-
Paris, Frankrike, 75015
- Fullført
- Hôpital Universitaire Necker Enfants Malades ( Site 1001)
-
-
Aquitaine
-
Pessac, Aquitaine, Frankrike, 33600
- Fullført
- CHU Bordeaux Haut-Leveque ( Site 1000)
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Frankrike, 44093
- Fullført
- Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1002)
-
-
Nord
-
Lille, Nord, Frankrike, 59037
- Fullført
- CHU Lille - Institut Coeur Poumon ( Site 1005)
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille, Provence-Alpes-Côte d'Azur Region, Frankrike, 13005
- Fullført
- Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1003)
-
-
-
-
-
Dublin, Irland, D12 N512
- Rekruttering
- Children's Health Ireland (CHI) at Crumlin ( Site 1400)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 01-4282854
-
-
-
-
Liguria
-
Genoa, Liguria, Italia, 16147
- Rekruttering
- IRCCS Istituto Giannina Gaslini ( Site 1603)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +3901056363993
-
-
Lombardy
-
Milan, Lombardy, Italia, 20154
- Rekruttering
- Ospedale dei Bambini "Vittore Buzzi" ( Site 1606)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +390263635733
-
-
Piedmont
-
Turin, Piedmont, Italia, 10126
- Rekruttering
- Ospedale Infantile Regina Margherita ( Site 1604)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +390113131853
-
-
Roma
-
Rome, Roma, Italia, 00165
- Rekruttering
- Ospedale Pediatrico Bambino Gesù IRCCS ( Site 1602)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +390668592217
-
-
Tuscany
-
Florence, Tuscany, Italia, 50139
- Fullført
- A.O.Universitaria Meyer ( Site 1600)
-
-
Veneto
-
Padova, Veneto, Italia, 35128
- Rekruttering
- Azienda Ospedale - Università Padova ( Site 1601)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0498213558
-
-
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Kroatia, 10000
- Rekruttering
- Klinički bolnički centar Zagreb ( Site 3700)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0038512367590
-
-
-
-
-
Kuala Lumpur, Malaysia, 50400
- Rekruttering
- Institut Jantung Negara ( Site 1705)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 603-26178465
-
Kuala Lumpur, Malaysia, 50300
- Rekruttering
- Hospital Tunku Azizah-Paediatric ( Site 1700)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +60326003000
-
-
Kelantan
-
Kota Bharu, Kelantan, Malaysia, 16150
- Rekruttering
- Hospital Pakar Universiti Sains Malaysia ( Site 1703)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +6097673000
-
-
Kuala Lumpur
-
Lembah Pantai, Kuala Lumpur, Malaysia, 59100
- Rekruttering
- University Malaya Medical Centre ( Site 1701)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +60479492351
-
-
Sabah
-
Kota Kinabalu, Sabah, Malaysia, Kota Kinab
- Rekruttering
- Hospital Queen Elizabeth II ( Site 1706)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +6088324600
-
-
-
-
-
Aguascalientes, Mexico, 20129
- Rekruttering
- Centro de Atención e Investigación Clínica ( Site 1813)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +525543673716
-
Colima, Mexico, 28000
- Rekruttering
- UROLAP ( Site 1812)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +523121552653
-
México, Mexico, 14080
- Rekruttering
- Instituto Nacional de Cardiologia Ignacio Chavez ( Site 1804)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +525520917905
-
-
Guanajuato
-
León, Guanajuato, Mexico, 37000
- Rekruttering
- Morales Vargas Centro de Investigacion S. C. ( Site 1810)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +524777160714
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44690
- Rekruttering
- CINVEC Medica ( Site 1814)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +523338012160
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 04530
- Rekruttering
- Instituto Nacional de Pediatria ( Site 1803)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +525556069738
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 66460
- Rekruttering
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Pediatria ( Site 1816)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +528183486173
-
-
State of Mexico
-
Hacienda de Las Palmas, State of Mexico, Mexico, 52763
- Rekruttering
- INVECORDIS S.C. ( Site 1808)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 5552469710
-
-
Tamaulipas
-
Ciudad Madero, Tamaulipas, Mexico, 89440
- Rekruttering
- Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 1800)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +528331260055
-
-
-
-
-
Groningen, Nederland, 9713 GZ
- Rekruttering
- University Medical Center Groningen ( Site 1901)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 31503612800
-
Utrecht, Nederland, 3584 CX
- Rekruttering
- Universitair Medisch Centrum Utrecht ( Site 1902)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 31 88 75 547
-
-
South Holland
-
Rotterdam, South Holland, Nederland, 3015 CN
- Rekruttering
- Erasmus Medisch Centrum ( Site 1900)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0031650162663
-
-
-
-
-
Auckland, New Zealand, 1023
- Rekruttering
- Auckland City Hospital ( Site 2000)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +6493670009
-
-
-
-
Lima
-
Jesús María, Lima, Peru, 15072
- Fullført
- Instituto Nacional Cardiovascular INCOR Carlos Peschiera Carrillo - EsSalud ( Site 2100)
-
-
Lima region
-
San Borja, Lima region, Peru, 15037
- Rekruttering
- Instituto Nacional de Salud del Nino San Borja ( Site 2105)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +512300600
-
-
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen, 80-952
- Fullført
- Uniwersyteckie Centrum Kliniczne-Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca ( Site 2302)
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Fullført
- Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 2402)
-
Porto, Portugal, 4200-319
- Aktiv, ikke rekrutterende
- Unidade Local de Saúde de São João ( Site 2403)
-
-
Lisbon District
-
Lisbon, Lisbon District, Portugal, 2790-134
- Fullført
- Unidade Local de Saude Lisboa Ocidental - Hospital de Santa Cruz ( Site 2401)
-
-
-
-
Makkah Al Mukarramah
-
Jeddah, Makkah Al Mukarramah, Saudi-Arabia, 23433
- Rekruttering
- King Faisal Specialist Hospital ( Site 4130)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +966533842107
-
-
Riyadh Region
-
Al Ahsa, Riyadh Region, Saudi-Arabia, 31982
- Rekruttering
- King Abdullah International Medical Research Center ( Site 4145)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +966506920153
-
Riyadh, Riyadh Region, Saudi-Arabia, 12713
- Rekruttering
- King Faisal Specialist Hospital and Research Center ( Site 4100)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +966114647272
-
Riyadh, Riyadh Region, Saudi-Arabia, 11426
- Rekruttering
- King Abdul Aziz Medical City - AlRiyadh ( Site 4110)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +966112520088
-
-
-
-
Beograd
-
Belgrade, Beograd, Serbia, 11000
- Rekruttering
- Childrens University Hospital ( Site 4200)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +381641212915
-
Belgrade, Beograd, Serbia, 11000
- Rekruttering
- Institut za zdravstvenu zastitu majke i deteta Srbije ( Site 4220)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +381658405885
-
-
Vojvodina
-
Novi Sad, Vojvodina, Serbia, 21000
- Rekruttering
- Institute for Child and Youth Helth Care of Vojvodina ( Site 4210)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +381642115233
-
-
-
-
South West
-
Singapore, South West, Singapore, 119074
- Rekruttering
- National University Hospital-Paediatrics ( Site 2600)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 67795555
-
Singapore, South West, Singapore, 229899
- Rekruttering
- KK Women's and Children's Hospital ( Site 2601)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 63941960
-
-
-
-
-
Madrid, Spania, 28046
- Rekruttering
- Hospital Universitario La Paz ( Site 2912)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34638372829
-
Seville, Spania, 41013
- Fullført
- HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2907)
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spania, 08950
- Rekruttering
- Hospital Sant Joan de Déu-Pediatric cardiology ( Site 2902)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34 932532100
-
-
Catalonia
-
Barcelona, Catalonia, Spania, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron ( Site 2903)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 934893135
-
-
La Coruna
-
A Coruña, La Coruna, Spania, 15009
- Rekruttering
- Hospital Materno-Infantil Teresa Herrera ( Site 2905)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 0034689979147
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spania, 28007
- Rekruttering
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2904)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +34915290523
-
-
-
-
-
Newcastle upon Tyne, Storbritannia, NE7 7DN
- Rekruttering
- Freeman Hospital ( Site 3400)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 07899895040
-
-
London, City of
-
London, London, City of, Storbritannia, WC1N 3JH
- Rekruttering
- Great Ormond Street Hospital For Children NHS Foundation Trust ( Site 3401)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 020 7405 9200
-
-
-
-
Skåne County
-
Lund, Skåne County, Sverige, 22185
- Rekruttering
- Skånes Universitetssjukhus Lund ( Site 3000)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +4646171000
-
-
Stockholm County
-
Solna, Stockholm County, Sverige, 171 64
- Rekruttering
- Astrid Lindgrens Barnsjukhus ( Site 3001)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +46812373124
-
-
-
-
-
Seoul, Sør -Korea, 03080
- Rekruttering
- Seoul National University Hospital ( Site 2803)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 82220720266
-
Seoul, Sør -Korea, 03722
- Rekruttering
- Severance Hospital, Yonsei University Health System ( Site 2800)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 82222288470
-
Seoul, Sør -Korea, 06351
- Rekruttering
- Samsung Medical Center ( Site 2801)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +82234103538
-
-
Kyongsangnam-do
-
Pusan, Kyongsangnam-do, Sør -Korea, 50612
- Fullført
- Pusan National University Yangsan Hospital ( Site 2802)
-
-
-
-
Western Cape
-
Cape Town, Western Cape, Sør-Afrika, 7700
- Rekruttering
- Children's Heart Disease Research Unit ( Site 2704)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 076 844 4074.
-
Cape Town, Western Cape, Sør-Afrika, 7500
- Fullført
- TREAD Research ( Site 2700)
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Rekruttering
- Maharaj Nakorn Chiang Mai Hospital-Department of Pediatrics ( Site 3201)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +66834739974
-
-
Bangkok
-
Bangkoknoi, Bangkok, Thailand, 10700
- Rekruttering
- Faculty of Medicine Siriraj Hospital ( Site 3200)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +6624197000
-
-
Changwat Khon Kaen
-
Muang, Changwat Khon Kaen, Thailand, 40002
- Fullført
- Faculty of Medicine - Khon Kaen University ( Site 3202)
-
-
-
-
-
Ankara, Tyrkia (Türkiye), 06230
- Rekruttering
- Hacettepe Universite Hastaneleri ( Site 3304)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +90 (0312) 305 25 85
-
Ankara, Tyrkia (Türkiye), 06490
- Rekruttering
- Baskent Universitesi Ankara Hastanesi ( Site 3301)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +90 (312) 246 66 66
-
Ankara, Tyrkia (Türkiye), 06800
- Rekruttering
- Ankara Bilkent Şehir Hastanesi. ( Site 3300)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +90 312 552 60 00
-
Istanbul, Tyrkia (Türkiye), 34668
- Fullført
- Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi ( Site 3302)
-
Izmir, Tyrkia (Türkiye), 35210
- Fullført
- S.B.Ü. DR. BEHÇET UZ ÇOCUK HASTALIKLARI VE CERRAHİSİ EĞİTİM VE ARAŞTIRMA HASTANESİ ( Site 3303)
-
-
-
-
-
Berlin, Tyskland, 13353
- Rekruttering
- Deutsches Herzzentrum Berlin ( Site 1101)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: + 49 30 4593 - 1000
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Tyskland, 79106
- Rekruttering
- Universitaetsklinikum Freiburg ( Site 1102)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +4976127043230
-
Heidelberg, Baden-Wurttemberg, Tyskland, 69120
- Fullført
- Universitaetsklinikum Heidelberg ( Site 1100)
-
-
Bavaria
-
Erlangen, Bavaria, Tyskland, 91054
- Rekruttering
- Kinderklinik des Uni-Klinikums Erlangen ( Site 1104)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +4991318533750
-
-
Lower Saxony
-
Hanover, Lower Saxony, Tyskland, 30625
- Rekruttering
- Medizinische Hochschule Hannover ( Site 1108)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +495115320
-
-
-
-
-
Budapest, Ungarn, 1096
- Rekruttering
- Gottsegen György Országos Kardiovaszkuláris Intézet-Gyermeksziv Kozpont ( Site 1300)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +3612151220
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Has symptomatic chronic heart failure (HF) resulting from systemic left ventricular (LV) systolic dysfunction.
- Has biventricular physiology with a morphologic systemic left ventricle.
- Is currently receiving stable medical therapy for HF.
- Has left ventricular ejection fraction (LVEF) <45% assessed within 3 months before randomization.
- Is of any sex/gender, from >28 days to <18 years of age inclusive. Must weigh ≥3 kg to participate.
- Female is eligible to participate if not pregnant or breastfeeding, and at least one of the following: is not a participant of childbearing potential (POCBP); or is a POCBP who uses a highly effective contraceptive method; has a negative highly sensitive pregnancy test; abstains from breastfeeding during the study intervention period and for at least 30 days after study intervention; and their medical history; their menstrual history, and recent sexual activity has been reviewed.
- Extension Period: Was randomized, received at least 1 dose of study intervention (vericiguat or placebo), did not permanently discontinue study intervention, and completed the Week 52 visit and safety follow-up period of the Base Period
Exclusion Criteria:
- Is clinically unstable-with at least one of the following: has symptomatic hypotension or is hypotensive for age, recent use of intravenous (IV) inotrope and/or IV vasodilator, or recent IV diuretic.
- Has a known allergy or sensitivity to vericiguat, any of its constituents, or any other soluble guanylate cyclase (sGC) stimulator.
- Has a history of single ventricle heart disease or has a morphologic systemic right ventricle.
- Has undergone heart transplantation, is awaiting heart transplantation United Network for Organ Sharing (UNOS) Class 1A or equivalent, is receiving continuous IV infusion of an inotrope, or has an implanted ventricular assist device.
- Has sustained or symptomatic dysrhythmia uncontrolled with drug or device therapy.
- Has had recent cardiovascular (CV) surgical procedure or percutaneous intervention to palliate or correct congenital CV malformations.
- Has unoperated or residual hemodynamically significant congenital cardiac malformations.
- Has hypertrophic or restrictive cardiomyopathy.
- Has active myocarditis or has been recently diagnosed with presumed or definitive myocarditis.
- Has acute coronary syndrome, undergone recent coronary intervention, or indication for coronary revascularization.
- Has symptomatic carotid stenosis or other symptomatic cerebrovascular disease
- Has severe pulmonary hypertension.
- Requires continuous home oxygen for significant pulmonary disease and/or has known interstitial lung disease.
- Has severe chronic kidney disease.
- Has hepatic disorder such as hepatic encephalopathy, hepatic laboratory abnormalities or Child Pugh Class C.
- Has a gastrointestinal or biliary disorder that could impair absorption, metabolism, or excretion of medications.
- Has significant bone disease (other than osteopenia) that in the assessment of the investigator can alter bone formation
- Has concurrent or anticipated concomitant use of phosphodiesterase type 5 inhibitors or an sGC stimulator.
- Has received a COVID-19 vaccination within 1 week before randomization.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Base Period: Vericiguat
Participants in the Base Period receive 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form for 52 weeks; or 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form for 52 weeks. |
2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
Andre navn:
0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
Andre navn:
|
|
Placebo komparator: Base Period: Placebo
Participants in the Base Period receive placebo for vericiguat administered orally once daily in tablet form for 52 weeks, or administered orally once daily in suspension form for 52 weeks. |
Placebo for vericiguat administered orally once daily in tablet form
Andre navn:
Placebo for vericiguat administered orally once daily in suspension form
Andre navn:
|
|
Eksperimentell: Extension Period: Vericiguat
Participants in the Extension Period receive either 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form; or 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form; following completion of the Base Period. |
2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
Andre navn:
0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Base Period: Change from baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)
Tidsramme: Baseline and Week 16 of Base Period
|
The change from baseline to Week 16 of the Base Period in log-transformed NT-proBNP will be reported. |
Baseline and Week 16 of Base Period
|
|
Extension Period: Percentage of participants with one or more adverse events (AEs)
Tidsramme: Includes data collected up to a maximum of approximately 8 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with one or more AEs in the Extension Period will be reported. |
Includes data collected up to a maximum of approximately 8 years
|
|
Extension Period: Percentage of participants who discontinued study drug due to an AE
Tidsramme: Includes data collected up to a maximum of approximately 8 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study drug in the Extension Period due to an AE will be reported. |
Includes data collected up to a maximum of approximately 8 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Base Period: Change from baseline to Week 52 in log-transformed NT-proBNP
Tidsramme: Baseline and Week 52 of Base Period
|
The change from baseline to Week 52 of the Base Period in log-transformed NT-proBNP will be reported. |
Baseline and Week 52 of Base Period
|
|
Base Period: First event of cardiovascular (CV) death, heart failure hospitalization (HFH), or worsening of heart failure (HF) without hospitalization
Tidsramme: Up to Week 54 of Base Period
|
The time from randomization to the first event of CV death, HFH, or worsening of HF without hospitalization will be reported for the Base Period. |
Up to Week 54 of Base Period
|
|
Base Period: Percentage of participants with one or more adverse events (AEs)
Tidsramme: Up to Week 54 of Base Period
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with one or more AEs in the Base Period will be reported. |
Up to Week 54 of Base Period
|
|
Base Period: Percentage of participants who discontinued study drug due to an AE
Tidsramme: Up to Week 52 of Base Period
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study drug in the Base Period due to an AE will be reported. |
Up to Week 52 of Base Period
|
|
Base Period: Area under the curve from time 0-24 hours post-dose (AUC0-24) of plasma vericiguat
Tidsramme: Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
Blood samples were collected at pre-specified time points pre- and post-dose and used to estimate the area under the curve from time 0-24 hours post-dose (AUC0-24) of plasma vericiguat. |
Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
|
Base Period: Half-life (t1/2) of vericiguat in plasma
Tidsramme: Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
Blood samples were collected at pre-specified time points pre- and post-dose and used to estimate the t1/2 of vericiguat in plasma. |
Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
|
Base Period: Oral clearance (CL/F) of plasma vericiguat
Tidsramme: Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
Blood samples were collected at pre-specified time points pre- and post-dose and used to estimate the CL/F of vericiguat in plasma. |
Pre-dose, 2, 6, 16, 32 and 52 weeks post-dose (Base Period)
|
|
Extension Period: Change from extension period baseline to extension period Week 16 in NT-proBNP
Tidsramme: Extension Period Baseline (Study Week 54) and Extension Period Week 16 (Study Week 70)
|
The change from the Extension Period baseline to Week 16 of the Extension Period in log-transformed NT-proBNP will be reported. |
Extension Period Baseline (Study Week 54) and Extension Period Week 16 (Study Week 70)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Medical Director, Merck Sharp & Dohme LLC
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 1242-036
- MK-1242-036 (Annen identifikator: MSD)
- 2021-004399-33 (EudraCT-nummer)
- MK-1242-043 (Annen identifikator: MSD)
- 2022-501238-52-00 (Registeridentifikator: EU CT)
- U1111-1275-1768 (Registeridentifikator: UTN)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .